| VERICEL CORP. |
| USA |
| Gesundheit |
| US92346J1088 / A12FU4 |
| ATQP (Frankfurt) / VCEL (NASDAQ) |
| FRA:ATQP, ETR:ATQP, ATQP:GR, NASDAQ:VCEL |
| - |
| https://www.vcel.com/ |
|
Vericel Corporation is a biopharmaceutical company focused on the development and commercialization of innovative cellular therapies for patients with severe diseases and conditions. The company's primary purpose is to provide next-generation solutio..
>Volltext.. |
| 1431.89 Mio. EUR |
| 1398.5 Mio. EUR |
| 239.33 Mio. EUR |
| 19.57 Mio. EUR |
| 14.31 Mio. EUR |
| 0.28 EUR |
| 85.13 Mio. EUR |
| 86.71 Mio. EUR |
| 44.97 Mio. EUR |
| 2.8 |
| 2.64% |
| 40.5% |
| - |
| - |
| - |
| VERICEL, AASTROM |
| 05.04.26 |